I BJORK
Overview
Explore the profile of I BJORK including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
155
Citations
1815
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arocas V, Bock S, Raja S, Olson S, BJORK I
J Biol Chem
. 2001 Sep;
276(47):43809-17.
PMID: 11567021
Lys(114) of the plasma coagulation proteinase inhibitor, antithrombin, has been implicated in binding of the glycosaminoglycan activator, heparin, by previous mutagenesis studies and by the crystal structure of antithrombin in...
2.
Pol E, BJORK I
Protein Sci
. 2001 Aug;
10(9):1729-38.
PMID: 11514663
Cystatin B is unique among cysteine proteinase inhibitors of the cystatin superfamily in having a free Cys in the N-terminal segment of the proteinase binding region. The importance of this...
3.
Larsson H, Akerud P, Nordling K, Claesson-Welsh L, BJORK I
J Biol Chem
. 2001 Mar;
276(15):11996-2002.
PMID: 11278631
Latent antithrombin, an inactive antithrombin form with low heparin affinity, has previously been shown to efficiently inhibit angiogenesis and tumor growth. We now show that heat treatment similar to that...
4.
Estrada S, Olson S, BJORK I
Protein Sci
. 2001 Jan;
9(11):2218-24.
PMID: 11152132
The three-dimensional structures of cystatins, and other evidence, suggest that the flexible N-terminal region of these inhibitors may bind to target proteinases independent of the two rigid hairpin loops forming...
5.
Pavlova A, Krupa J, Mort J, Abrahamson M, BJORK I
FEBS Lett
. 2001 Jan;
487(2):156-60.
PMID: 11150500
Cystatins A and C were both shown to inhibit cathepsin B by a two-step mechanism, involving an initial weak interaction followed by a conformational change. Disruption of the major salt...
6.
Craven C, Baxter N, Murray E, Hill N, Martin J, Ylinenjarvi K, et al.
Biochemistry
. 2000 Dec;
39(51):15783-90.
PMID: 11123903
The solution structure of an N-terminally truncated and mutant form (M65L(2-98)) of the human cysteine protease inhibitor cystatin A has been reported that reveals extensive structural differences when compared to...
7.
Larsson H, Sjoblom T, Dixelius J, Ostman A, Ylinenjarvi K, BJORK I, et al.
Cancer Res
. 2000 Dec;
60(23):6723-9.
PMID: 11118058
Antithrombin is a plasma protein of the serpin superfamily that may occur as several conformational variants. The native form of antithrombin is a major regulator of blood clotting. In the...
8.
Olsson S, Pihlgren U, Ploen L, BJORK I
Eur J Histochem
. 2000 Sep;
44(2):171-8.
PMID: 10968365
Cysteine proteinase inhibitors of the cystatin superfamily have been identified in many living organisms. However, knowledge of the tissue distribution of such inhibitors is limited. To elucidate this distribution in...
9.
Arocas V, Turk B, Bock S, Olson S, BJORK I
Biochemistry
. 2000 Jul;
39(29):8512-8.
PMID: 10913257
The interaction of a well-defined pentasaccharide sequence of heparin with a specific binding site on antithrombin activates the inhibitor through a conformational change. This change increases the rate of antithrombin...
10.
Desai U, Swanson R, Bock S, BJORK I, Olson S
J Biol Chem
. 2000 Apr;
275(25):18976-84.
PMID: 10764763
The contribution of Arg(129) of the serpin, antithrombin, to the mechanism of allosteric activation of the protein by heparin was determined from the effect of mutating this residue to either...